- Home
- CATO vs IFRX Comparison
CATO vs IFRX Comparison
Compare CATO & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | IFRX |
|---|---|---|
| Founded | 1946 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.8M | 60.6M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CATO | IFRX |
|---|---|---|
| Price | $3.03 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 43.5K | ★ 280.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $649,806,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $12.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.71 |
| 52 Week High | $4.92 | $1.94 |
Technical Indicators
Market Signals| Indicator | CATO | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 50.88 |
| Support Level | $2.80 | $0.81 |
| Resistance Level | $3.22 | $1.16 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.43 | 77.95 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.